UKPDS-334 | 54 | 10 | 7.0 vs 7.9 |
-
No difference in major clinical outcomes* at 10 y† -
Benefits on surrogate outcomes (less microvascular disease after ≥ 6 y) -
Increase in serious hypoglycemia -
A follow-up study after 20 y saw decreased MI and all-cause death6
|
ADVANCE7 | 66 | 5 | 6.5 vs 7.3 |
-
No difference in major clinical outcomes* at 5 y -
Decrease in microvascular end points (NNT = 67 at 5 y), mostly nephropathy surrogates -
Increase in serious hypoglycemia (NNH = 83 at 5 y)
|
VADT8 (most participants had a history of CV problems) | 60 | 5.6 | 6.9 vs 8.4 |
-
No difference in major clinical outcomes* at 5.6 y -
Increased rate of serious adverse events (NNH = 15 at 5.6 y) -
Increase in serious hypoglycemia (NNH = 83 at 5.6 y)
|
ACCORD9 (35% of participants had a history of CV problems) | 62 | 3.5 | 6.4 vs 7.5 |
|